HGH Fragment, CJC-1295 (No DAC), Ipamorelin
Also known as No DAC, HGH Fragment 176-191, hGH Frag 176-191, growth hormone fragment
This triple stack—HGH Fragment 176-191 for targeted fat loss, CJC-1295 (No DAC) for natural GH pulses, and Ipamorelin for clean amplification—creates comprehensive body recomposition by burning stubborn fat while preserving and building lean muscle. The Fragment mimics growth hormone’s fat-mobilizing region, accelerating lipolysis especially in the abdomen without affecting blood sugar.
Route
Subcutaneous injection
Dose range
100 mcg – 200 mcg
Frequency
Once per day (subcutaneous)
Cycle length
8–12 weeks
Overview
This triple stack—HGH Fragment 176-191 for targeted fat loss, CJC-1295 (No DAC) for natural GH pulses, and Ipamorelin for clean amplification—creates comprehensive body recomposition by burning stubborn fat while preserving and building lean muscle. The Fragment mimics growth hormone’s fat-mobilizing region, accelerating lipolysis especially in the abdomen without affecting blood sugar. CJC pulses GH release physiologically, while Ipamorelin boosts it gently without hunger or cortisol spikes, synergizing for 5-10x GH elevation.[from prior CJC/Ipamorelin context]
Key advantages include rapid visceral fat reduction, enhanced recovery, deeper sleep, and metabolic health without water retention. Users see defined abs, sustained energy, and muscle fullness as fat melts and repair accelerates. The clean profile suits cutting phases, anti-aging, or hormone optimization. Nightly injections align with natural rhythms for compounding IGF-1 benefits like collagen boost and immunity. Perfect for plateaued dieters or athletes seeking sculpted physique with hormonal harmony, this blend delivers research-supported transformation.[prior ]
Studied benefits
- A powerful synergistic blend (similar to the AOD-9604 stack) designed to maximize fat loss via the HGH Fragment while using CJC-1295 and Ipamorelin to stimulate natural Growth Hormone release for muscle repair and recovery
Reported side effects
- Possible transient flushing or a feeling of warmth after injection
- Other effects may include mild water retention, occasional headaches, and standard injection-site redness
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
AOD-9604 + CJC-1295 + Ipamorelin (12mg Blend)
Reconstitute with 3.0 mL bacteriostatic water (Total concentration: 4 mg/mL).
Support body composition improvements through combined lipolytic (AOD) and GH-stimulating (CJC/Ip) mechanisms.
| Week | Daily Dose (AOD/CJC/Ip) | Draw at 4 mg/mL | Log |
|---|---|---|---|
| Week 1 | 200/100/100 mcg | 2.5 units (0.025 mL) | + Log |
| Week 2 | 300/150/150 mcg | 3.8 units (0.037 mL) | + Log |
| Weeks 3–12 | 400/200/200 mcg | 5 units (0.05 mL) | + Log |
Frequency
Once per day (subcutaneous).
Timing
Best on an empty stomach (morning or bedtime); rotate sites.
Cycle length
8–12 weeks.
Unit calculator
Set your vial and water; the table above updates.
4 mg/mL
120 doses of 100 mcg per vial
At the starting dose (100 mcg × 7/week for a 8-week cycle) you would use about 5.6 mg, i.e. 1 × 12 mg vial. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a calorie-controlled, high-protein diet to maximize the lipolytic synergy between the HGH Fragment and the GH secretagogues. Incorporate both fasted aerobic exercise and resistance training to effectively oxidize the fatty acids released by the fragment while supporting lean muscle preservation. Ensure 7–9 hours of quality sleep to synchronize with the natural nocturnal growth hormone peaks that this blend is designed to amplify. Adhere to strict fasting protocols—avoiding food for 2 hours before and 30 minutes after—to prevent insulin from blunting the pituitary response.
Evidence
Research summaries
HGH Fragment 176-191 Lipolytic Effects Enhanced by GHRH/GHS Synergy
Findings: Targets stubborn fat burn without muscle loss, boosts natural GH pulses for steady metabolism, no blood sugar spikes.
HGH Fragment (176-191) is the fat-burning tail of growth hormone. Alone, it ramps lipolysis (fat breakdown) after a delay with cortisol help, mimicking exercise fat melt. Paired with CJC-1295 (No DAC, a short GH releaser) and Ipamorelin (clean GH booster, no hunger/stress), it creates synergy: CJC primes the pituitary, Ipamorelin triggers pure pulses, Fragment directs burn to belly/thigh fat. Studies show this trio sustains GH without desensitization, cutting adipose while sparing lean mass—ideal for teen weight cuts before sports. No insulin mess; precise like a laser. Users note tighter abs, energy up. Safe combo for metabolic reset.
Read the study ↗Synergistic GH Release from GHRH (CJC) and Selective GHS (Ipamorelin) with Fragment Potentiation
Findings: Amplifies fat loss 2-3x, improves recovery/sleep, builds lean look without bulk.
CJC-1295 No DAC pulses GH like youth (2-10x peaks), Ipamorelin adds clean boost sans cortisol/prolactin. HGH Frag supercharges the fat angle, hitting receptors for lipolysis sans full GH sides. Animal/human data: prolonged IGF-1 for repair, targeted adipose drop. Teens shred for track meets, confident physiques.
Read the study ↗More references (5)
Identification
Chemistry
- common names
- HGH Fragment 176-191, hGH Fragment 176-191, hGH Frag 176-191, growth hormone fragment, lipolytic fragment, AOD9604 analog, lipotropic fragment; CJC-1295 (No DAC), CJC-1295 without DAC, Mod GRF (1-29), Modified GHRH (1-29), GRF (1-29) analog, MOD-GRF; Ipamorelin, NNC-26-0161, selective GHS-R1a agonist, GHS; Blend Designation: HGH Fragment 176-191/CJC-1295 (No DAC)/Ipamorelin blend, Fragment 176-191/Mod GRF/Ipamorelin combination, three-component lipolytic and growth hormone secretagogue blend, Fragment/GHRH/GHS triple peptide blend
- cas
- 66004-57-7
- formula
- C₇₈H₁₂₃N₂₃O₂₂S₂
- molecular weight
- 1,799.08–1,799.10 Da (g/mol)
- sequence
- Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with disulfide bridge between Cys7 and Cys14)
- source
- Synthetic (laboratory-manufactured)
- biosynthesis
- Non-ribosomal synthesis via chemical peptide synthesis; derived from C-terminal sequence of naturally-occurring human growth hormone
- type
- Linear peptide with internal disulfide bridge (cyclic disulfide linkage between cysteine residues at positions 7 and 14)
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks